Location: United States, California, Irvine
Employees: 51-200
Mentions in press and media 12
| Date | Title | Description |
| 31.10.2024 | Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology | Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases cannot be accurately modeled by animals, ... |
| 24.10.2024 | Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved... | Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited dis... |
| 06.09.2024 | Medera Inc. Merges with Keen Vision Acquisition: A New Era for Cardiovascular Innovation | In a bold move that could reshape the landscape of cardiovascular treatment, Medera Inc. has announced its merger with Keen Vision Acquisition Corporation (KVAC). This merger, set to close in the fourth quarter of 2024, positions Medera as ... |
| 05.09.2024 | Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation | Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discov... |
| 05.09.2024 | Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation | Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discov... |
| 28.02.2024 | Medera’s Sardocor Granted FDA Orphan Drug Designation for DMD-associated cardiomyopathy Gene Therapy | BOSTON, MA, UNITED STATES, February 28, 2024 /EINPresswire.com/ -- Sardocor Corp., the clinical-stage gene therapy subsidiary of Medera Inc., with a broad pipeline of adeno-associated virus (AAV)-based treatments for cardiovascular diseases... |
| 14.02.2024 | MEDERA’S SARDOCOR ANNOUNCES FAST TRACK DESIGNATION AND DOSING OF 3 PATIENTS IN FIRST-IN-HUMAN HFpEF GENE THERAPY TRIAL | BOSTON, MA, UNITED STATES, February 14, 2024 /EINPresswire.com/ -- • Heart failure is a global pandemic with an estimated 64.3 million cases worldwide. • Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart fail... |
| 21.11.2023 | MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR | MEDERA’S NOVOHEART PARTNERS NATIONAL HEART CENTRE SINGAPORE TO DEVELOP ASIA’S FIRST BIOENGINEERED HUMAN HEART-IN-A-JAR WITH HEART FAILURE FOR PRECISION MEDICINE BOSTON, MASSACHUSETTS, UNITED STATES, November 21, 2023 /EINPresswire.com/ -- M... |
| 01.12.2022 | MEDERA’S SARDOCOR ANNOUNCES FDA CLEARANCE OF IND FOR FIRST-IN-HUMAN GENE THERAPY CLINICAL TRIAL FOR DMD CARDIOMYOPATHY | BOSTON, MASSACHUSETTS, UNITED STATES, December 1, 2022 /EINPresswire.com/ -- • With modern therapeutic strategies to prolong life expectancy, an increasing number of Duchenne Muscular Dystrophy (DMD) patients survive to develop cardiomyopat... |
| 18.11.2022 | MEDERA RECEIVES FDA CLEARANCE FOR A FIRST-IN-HUMAN GENE THERAPY TRIAL FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION | BOSTON, MASSACHUSETTS, UNITED STATES, November 18, 2022 /EINPresswire.com/ -- • Heart failure is a global pandemic with an estimated 64.3 million cases worldwide • Heart failure with preserved ejection fraction (HFpEF) accounts for half of ... |
Show more